RxDoctor Payments Data

Ashley Hammer, NP

Acute Care · Evansville, INNPI 1609234319

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,652 of the $1,917 with a category attached, or 86.2%. 8 manufacturers reported payments, led by Atricure, Inc. at 49.4% of the total. Reporting peaked in 2022 at $829 and has fallen 91.6% since, to $70 in 2025.

$1,917in general payments, 2019–2025

Across 27 payments — averaging $70.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Atricure, Inc.$947
  • Boston Scientific$341
  • Edwards Lifesciences$302
  • AstraZeneca$78
  • Inari Medical, Inc.$74
  • AbbVie$70
  • plus $104 from 2 others

What the payments were for

  • Travel & lodging$26514%
  • Food & beverage$1,65286%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,917 in reported general payments places this provider in the 80th percentile of 240 acute care providers in Indiana.

See all acute care providers in Indiana

Medicare billing

Part B allowed, 2024
$53,261
Medicare patients
424
Services billed
1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban794$771,060
XareltoRivaroxaban134$114,688
MultaqDronedarone Hcl65$94,474
EntrestoSacubitril/Valsartan76$78,048
JardianceEmpagliflozin74$52,417
FarxigaDapagliflozin Propanediol16$14,077
Repatha SureclickEvolocumab15$8,419
Dofetilide84$7,261
Metoprolol Succinate464$5,516
Diltiazem 24hr Er (Cd)Diltiazem Hcl121$2,802
Amiodarone Hcl236$2,677
Isosorbide Mononitrate ErIsosorbide Mononitrate199$2,576
Atorvastatin Calcium231$1,731
Amlodipine Besylate286$1,288
Losartan Potassium117$1,258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$78$14,07716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 240 acute care providers in Indiana.

Other acute care in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →